At a glance
- Originator GlaxoSmithKline
- Class Antidepressants; Small molecules
- Mechanism of Action Monoamine oxidase A inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 16 Nov 1999 Profile reviewed but no significant changes made
- 03 Jan 1997 No-Development-Reported for Depression in Spain (Unknown route)